Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few immune alterations are described in humans. We retrospectively studied hematologic and immunological parameters in 72 chronic myeloid leukemia and 15 gastrointestinal stromal tumor patients treated with imatinib at standard dosage and in 20 chronic myeloid leukemia patients treated before the introduction of imatinib in clinical practice. Both chronic myeloid leukemia and gastrointestinal stromal tumor patients developed a significant reduction of gammaglobulin and immunoglobulin serum levels. No significant hypogammaglobulinemia was observed in chronic myeloid leukemia patients in the pre-imatinib era. These data demonstrate that imatinib treatment induces hypogammaglobulinemia that can reach a severe entity in 10% of cases, both in chronic myeloid leukemia and in gastrointestinal stromal tumor patients. Prospective studies are needed to evaluate immune humoral alterations and to define the real incidence of infectious events, including viral reactivations.

Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor / Santachiara, Rita; Maffei, Rossana; Martinelli, Silvia; Arcari, Annalisa; Piacentini, Federico; Trabacchi, Elena; Alfieri, Pierluigi; Ferrari, Angela; Leonardi, Giovanna; Luppi, Gabriele; Longo, Giuseppe; Vallisa, Daniele; Marasca, Roberto; Torelli, Giuseppe. - In: HAEMATOLOGICA. - ISSN 0390-6078. - ELETTRONICO. - 93:8(2008), pp. 1252-1255. [10.3324/haematol.12642]

Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor

SANTACHIARA, Rita;MAFFEI, Rossana;MARTINELLI, Silvia;PIACENTINI, Federico;ALFIERI, PIERLUIGI;MARASCA, Roberto;TORELLI, Giuseppe
2008

Abstract

Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few immune alterations are described in humans. We retrospectively studied hematologic and immunological parameters in 72 chronic myeloid leukemia and 15 gastrointestinal stromal tumor patients treated with imatinib at standard dosage and in 20 chronic myeloid leukemia patients treated before the introduction of imatinib in clinical practice. Both chronic myeloid leukemia and gastrointestinal stromal tumor patients developed a significant reduction of gammaglobulin and immunoglobulin serum levels. No significant hypogammaglobulinemia was observed in chronic myeloid leukemia patients in the pre-imatinib era. These data demonstrate that imatinib treatment induces hypogammaglobulinemia that can reach a severe entity in 10% of cases, both in chronic myeloid leukemia and in gastrointestinal stromal tumor patients. Prospective studies are needed to evaluate immune humoral alterations and to define the real incidence of infectious events, including viral reactivations.
2008
93
8
1252
1255
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor / Santachiara, Rita; Maffei, Rossana; Martinelli, Silvia; Arcari, Annalisa; Piacentini, Federico; Trabacchi, Elena; Alfieri, Pierluigi; Ferrari, Angela; Leonardi, Giovanna; Luppi, Gabriele; Longo, Giuseppe; Vallisa, Daniele; Marasca, Roberto; Torelli, Giuseppe. - In: HAEMATOLOGICA. - ISSN 0390-6078. - ELETTRONICO. - 93:8(2008), pp. 1252-1255. [10.3324/haematol.12642]
Santachiara, Rita; Maffei, Rossana; Martinelli, Silvia; Arcari, Annalisa; Piacentini, Federico; Trabacchi, Elena; Alfieri, Pierluigi; Ferrari, Angela;...espandi
File in questo prodotto:
File Dimensione Formato  
1252.full.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 105.35 kB
Formato Adobe PDF
105.35 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1060806
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 20
social impact